Cipla

Cipla FCF per Share

The Free Cash Flow per Share of Cipla (CIPLA.NS) as of Oct 10, 2026 is 31.25 INR. In the previous year, Free Cash Flow per Share was 47.54 INR — a change of -34.26% (lower).

FCF per Share

31.25INR

YoY

-34.26%

Last updated:

Free Cash Flow per Share of Cipla is 2026 31.25 INR. Free Cash Flow per Share of Cipla was 2025 47.54 INR. It decreases by -34.26% lower compared to the previous year.

The Cipla FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2019
14.42 INR
Jan 1, 2020
25.60 INR
Jan 1, 2021
36.35 INR
Jan 1, 2022
32.51 INR
Jan 1, 2023
25.43 INR
Jan 1, 2024
34.45 INR
Jan 1, 2025
47.54 INR
Jan 1, 2026
31.25 INR
The Cipla FCF per Share history
YEARFCF per ShareYoY
31.25INR-34.26%
47.54INR+37.99%
34.45INR+35.45%
25.43INR-21.76%
32.51INR-10.57%
36.35INR+41.99%
25.60INR+77.49%
14.42INR+79.89%
8.02INR-48.13%
15.46INR+87.69%
8.24INR+25.86%
6.54INR-46.92%
12.33INR—
Access this data via the Eulerpool API

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cipla stock

Free Cash Flow per Share of Cipla is 31.25 INR in 2026.

Free Cash Flow per Share of Cipla changed from 47.54 INR to 31.25 INR, representing a -34.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Cipla since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

Cash Flow — Cipla

All Key Metrics — Cipla